The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18–59 Years and over 60 Years Based on Two Randomized Controlled Trials in China
Previous reports have shown that heterologous boosting with the AD5-vectored COVID-19 vaccine Convidecia based on a primary series of two doses of inactivated vaccine induces increasing immune responses. However, the immune persistence until 6 months after the heterologous prime-boost immunization w...
Збережено в:
| Автори: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2023-12-01
|
| Серія: | Vaccines |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2076-393X/11/12/1815 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|